about
Role of Riboflavin- and UV Light-Treated Plasma in Prevention of Transfusion-Related Acute Lung Injury.Characterization of monoclonal gammopathy of undetermined significance by calorimetric analysis of blood serum proteome.The utility of pathogen inactivation technology: a real-life example of Leishmania infantum inactivation in platelets from a donor with an asymptomatic infectionDetection and Quantification of Viable and Nonviable Trypanosoma cruzi Parasites by a Propidium Monoazide Real-Time Polymerase Chain Reaction Assay.Transfusion-transmitted leishmaniasis: a practical review.Collection, storage, inspection and quality control of platelet concentrates obtained by apheresis: The situation in Spain.Strategies for reducing the risk of transfusion-transmitted leishmaniasis in an area endemic for Leishmania infantum: a patient- and donor-targeted approach.The effectiveness of riboflavin and ultraviolet light pathogen reduction technology in eliminating Trypanosoma cruzi from leukoreduced whole blood.Evidence of meaningful levels of Trypanosoma cruzi in platelet concentrates from seropositive blood donors.Practical issues that should be considered when planning the implementation of pathogen reduction technology for plateletpheresis.Why are platelets the most frequently mentioned blood component in Chagas transfusion transmission reports?A possible case of Chagas disease reactivation after a bone marrow transplant.Reducing the financial impact of pathogen inactivation technology for platelet components: our experience.A lesson to learn from Hemovigilance: The impact of nurses' transfusion practice on mistransfusion.Where do Trypanosoma cruzi go? The distribution of parasites in blood components from fractionated infected whole blood.Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain).Passive haemovigilance of blood components treated with a riboflavin-based pathogen reduction technology.Pathogen inactivation technology applied to a blood component collected from an asymptomatic carrier of Leishmania infantum: a case report.MALDI-TOF analysis of blood serum proteome can predict the presence of monoclonal gammopathy of undetermined significanceOur experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient careA possible case of transfusion-transmitted visceral leishmaniasisUsefulness of platelet (PLT) pathogen inactivation technology: a case of Sphingomonas paucimobilis inactivation in an apheresis PLT unitTreatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti-PP1Pk or anti-K immunization: a report of two patients[Evaluation of the polyethyleneglycol antiglobulin test in the detection and identification of erythrocyte antibodies][The Budd-Chiari syndrome coinciding with a hemolytic crisis in a patient with paroxysmal nocturnal hemoglobinuria][Severe hemolytic anemia secondary to cytomegalovirus infection in an immunocompetent adult]Aggregates in platelet concentratesUse and safety of riboflavin and UV light-treated platelet transfusions in children over a five-year period: focusing on neonatesLeucoreduction for preventing parasite transfusion-transmission: an overlooked strategyPathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting
P50
Q33863382-A0679421-A711-45B2-BA98-7335197443D3Q35202780-0EEC38D4-D366-482B-A6AF-AF1FA5A4361EQ36393465-914C9CD3-E6EF-412C-BF1B-3D1C07D7C27CQ36958490-353FDC4A-71F4-49BF-9B63-DD1C6548CEC9Q38784179-E605D25C-E779-4287-8A46-242C57F6BB78Q38893925-A04F5CB3-47E6-4D73-B2B1-3090A6F01DD0Q40219047-B79F45BA-4FE5-4D66-913A-130B388F5C32Q40246814-A0C3CE8A-365A-4089-BE95-73446A12E4F5Q41482695-29955B16-E88A-438C-A09D-B7F7CCD547ABQ42175787-03EE060E-9776-4F50-92EB-CD56B9AC235CQ42367937-684FDF34-A8A9-477A-9974-74DD2B082A58Q42430765-7FB45CAD-635E-46B3-900C-9B61496FC3D6Q44023975-28840F40-E274-4296-AF87-39FF1DB262C4Q47684769-8F8D84DE-B173-425B-84FB-1F714E55C2C9Q50237153-F3B1342B-9459-4D9D-8E42-0053CFA6AC6AQ50652310-C6FD20E4-64AC-452C-9BE8-BA46D9C6DA34Q53496484-5C4CE333-B424-45EC-9B87-BB4E58C0C12AQ54304366-B1D9BF5A-3D7F-49D0-92CB-30F136A3425DQ58803709-E28BE149-C6C5-4A1A-BC28-605C70A9AD61Q58854036-6879D561-B41F-40DB-A1A5-5E84ABA38C32Q58854041-94C348DF-C022-4E39-A038-0AC0DEE10956Q58854043-D95774AC-F727-486C-BEF6-9870C6FE1A74Q73870268-82E29A71-7A99-4266-BF33-7B5840B016A1Q74521113-AE8A8CA2-E260-47EC-AEDC-B8D1E4454BC1Q74630613-3F757178-BFE5-4402-86C7-4C0D023AC3F3Q74762765-9E72C7D1-D360-4493-B369-D7A0B883BB7BQ85334956-2A2AA3A8-F217-4AD9-8081-ABD20BA0D6B2Q90515281-9022E1DF-907D-4C45-BD6E-2D1A045CD29DQ92029832-63A6DD00-2AB4-40C1-9D41-7912B95DC95CQ92044626-FEE039CC-9D76-4481-A102-B9A1DEC9B1E2
P50
description
researcher ORCID ID = 0000-0001-9631-6541
@en
wetenschapper
@nl
name
Teresa Jimenez-Marco
@ast
Teresa Jimenez-Marco
@en
Teresa Jimenez-Marco
@es
Teresa Jimenez-Marco
@nl
type
label
Teresa Jimenez-Marco
@ast
Teresa Jimenez-Marco
@en
Teresa Jimenez-Marco
@es
Teresa Jimenez-Marco
@nl
prefLabel
Teresa Jimenez-Marco
@ast
Teresa Jimenez-Marco
@en
Teresa Jimenez-Marco
@es
Teresa Jimenez-Marco
@nl
P106
P21
P31
P496
0000-0001-9631-6541